Highlights

• Microba Life Sciences secured $5 million through a placement at $0.05 per share, with strategic shareholder Sonic Healthcare investing $1.5 million.
• The company expects the funding and operational efficiencies to support a path toward company-wide cashflow break-even on a run-rate basis during CY2027.
• Core testing sales have increased for 11 consecutive quarters, with 106% growth over the past 12 months and a new diagnostics product scheduled for launch in Q3 CY26.

Microba Life Sciences Ltd (ASX:MAP) has emerged as one of the more closely watched healthcare technology companies on the Australian Securities Exchange following its latest capital raising announcement. The…